Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Yusuke Nakamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-8461-749X; OpenAlex author ID A5101940701. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 12

  1. Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Co-author DOI 10.3389/fimmu.2025.1571182↗
  2. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. Co-author DOI 10.3390/ijms231911521↗
  3. Amplification of mutant KRAS G12D in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report. Co-author DOI 10.3892/mco.2021.2334↗
  4. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. Co-author DOI 10.1371/journal.pone.0202272↗
  5. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  6. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗
  7. Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Co-author DOI 10.18632/oncotarget.21939↗
  8. Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown. Co-author DOI 10.1016/j.neo.2016.03.005↗
  9. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  10. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Co-author DOI 10.1158/1078-0432.ccr-11-1387↗
  11. C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage. Last author DOI 10.1002/gcc.20828↗
  12. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Co-author DOI 10.1038/sj.bjc.6606052↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasutoshi Kimura · 2 shared papers, 2021–2022 · strength 0.29
  2. Fabio Pittella-Silva · 2 shared papers, 2021–2022 · strength 0.29
  3. Siew‐Kee Low · 2 shared papers, 2021–2022 · strength 0.29
  4. Masayo Motoya · 2 shared papers, 2021–2022 · strength 0.29
  5. Chika Iwamoto · 1 shared paper, 2025 · strength 0.20
  6. Masafumi Nakamura · 1 shared paper, 2025 · strength 0.20
  7. Kohei Nakata · 1 shared paper, 2025 · strength 0.20
  8. Toshiya Abe · 1 shared paper, 2025 · strength 0.20
  9. Nao Fujimori · 1 shared paper, 2025 · strength 0.20
  10. Koki Oyama · 1 shared paper, 2025 · strength 0.20
  11. Naoki Ikenaga · 1 shared paper, 2025 · strength 0.20
  12. Hiroto Tanaka · 1 shared paper, 2025 · strength 0.20
  13. Takashi Morisaki · 1 shared paper, 2025 · strength 0.20
  14. Hideya Onishi · 1 shared paper, 2025 · strength 0.20
  15. Toru Nakamura · 2 shared papers, 2017–2022 · strength 0.18
  16. Satoshi Hirano · 2 shared papers, 2017–2022 · strength 0.18
  17. Kazunori Watanabe · 1 shared paper, 2022 · strength 0.12
  18. Haruo Iguchi · 2 shared papers, 2017 · strength 0.09
  19. Masaaki Oka · 2 shared papers, 2017 · strength 0.09
  20. Tomio Ueno · 2 shared papers, 2017 · strength 0.09
  21. Takashi Hatori · 2 shared papers, 2017 · strength 0.09
  22. Yoshitaro Shindo · 2 shared papers, 2017 · strength 0.09
  23. Nobuaki Suzuki · 2 shared papers, 2017 · strength 0.09
  24. Tetsuya Ikemoto · 2 shared papers, 2017 · strength 0.09
  25. Yuzo Umeda · 2 shared papers, 2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.